1)Chanson P, Maiter D:The epidemiology, diagnosis and treatment of prolactinomas;The old and the new. Best Pract Res Clin Endocrinol Metab 33:101290, 2019
2)Lee DY, et al:Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems. Am J Obstet Gynecol 206:213.e1-5, 2012
3)Melmed S, et al, et al:Diagnosis and treatment of hyperprolactinemia;An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273-288, 2011
4)Delgrange E, et al:Potential hook effect in prolactin assay in patients with giant prolactinoma. Clin Endocrinol(Oxf) 45:506-507, 1996
5)Leslie H, et al:Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 86:2743-2746, 2001
6)Gillam MP, et al:Advances in the treatment of prolactinomas. Endocr Rev 27:485-534, 2006
7)Stiles CE, et al:A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline. J Clin Endocrinol Metab, 2018(online ahead of print)
8)Ciric I, et al:Complications of transsphenoidal surgery;Results of a national survey, review of the literature, and personal experience. Neurosurgery 40:225-236;discussion 236-237, 1997
9)Krupp P, Monka C:Bromocriptine in pregnancy;Safety aspects. Klin Wochenschr 65:823-827, 1987
10)Malter MP, et al:Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67:470-478, 2010
11)Raverot G, et al:European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1-G24, 2018
12)Lourenço DM Jr, et al:Multiple endocrine neoplasia type 1 in Brazil;MEN1 founding mutation, clinical features, and bone mineral density profile. Eur J Endocrinol 159:259-274, 2008